"Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis"
http://www.nejm.org/doi/full/10.1056/NEJMoa1314768?query=featured_home
"CONCLUSIONS
Patients treated with dupilumab had marked and rapid improvement in all the evaluated measures of atopic dermatitis disease activity. Side-effect profiles were not dose-limiting. (Funded by Regeneron Pharmaceuticals and Sanofi; ClinicalTrials.gov numbers,NCT01259323, NCT01385657, NCT01639040, and NCT01548404.)"
No comments:
Post a Comment